[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
Dyskinesias induced by L-dopa are involuntary and abnormal movements which lead to disablement and are observed in a lot of patients after some years of treatment. No drug has proved its efficacy for this indication. The use of D2 dopaminergic agonists as first treatment can delay their onset, delaying the need for L-dopa. New dopaminergic drugs, either with longer elimination half life or with specificity for subtypes of dopamine receptors may allow these dyskinesias to be managed more efficaciously. New non-dopaminergic, serotoninergic, adrenergic, opiate or gluamate drugs could offer antidyskinesia properties. The study of Parkinson disease's model in the methyl phenyltetrahydropyridine (MPT)-treated primate and the improvement in clinical evaluation of these dyskinesias could lead, in the short or medium term, to the discovery of new pharmarcological strategies, dealing more efficaciously with this serious adverse effect of L-dopa treatment.
Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 455, Toulouse, France.
O
O
Rascol
C
C
Brefel-Courbon
O
O
Blin
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D011323:Primates
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens.